S John Weroha

8PUBLICATIONS
134CO-AUTHORS
Learning analyticsMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 25, 2026
Factors affecting trainees' preferred timing of clinical clerkships during MD-PhD training.

|Jan 14, 2026
Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer.

Julie R Duffield, Xiaonan Hou, Benjamin W Wilson

|Jun 23, 2024
Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models.

Manisha Taya, Xiaonan Hou, Jennifer T Veneris

|Mar 26, 2024
A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies.

Eleftheria Kalogera, Wendy K Nevala, Heidi D Finnes

|May 30, 2023
Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.

Chunling Hu, Anil Belur Nagaraj, Hermela Shimelis

|Oct 07, 2022
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.

Gwo Yaw Ho, Elizabeth L Kyran, Justin Bedo

Pageof 2

Frequent Collaborators

2 joint publications

Ann L Oberg

2 joint publications

Scott H Kaufmann

2 joint publications

Melissa C Larson

2 joint publications

Xiaonan Hou